65,437 trials
Essential Tremor
Primary: Change From Baseline in The Essential Tremor Rating Assessment Scale (TETRAS) Performance Subscale Item 4 (Upper Limb) Total Score on Day 91 in the Monotherapy Cohort…
Colorectal Cancer Metastatic
Primary: Evaluate the Overall Survival — 97; 368 days
Atrial Fibrillation · Atrial Flutter
Primary: Number of Subjects With a Primary Safety Event — 0 Participants
Alcohol Drinking · Alcohol Abuse
Primary: Drinks Per Week as Assessed by the Daily Drinking Questionnaire — 6.8; 6.0; 7.1 drinks per week — p=.646
Brain Metastases
Primary: Maximum Tolerated Dose of Five Fraction Stereotactic Radiotherapy — 35; 30 Gy
Lung Cancer
Primary: Patient-reported Quality of Life — 99.7; 97.7 units on a scale — p=0.04
Chronic Low-back Pain
Primary: Oswestry Disability Index Score (ODI) — 24.84; 25.34; 17.94; 18.99 units on a scale — p=0.412
Non-Therapeutic Body Modification
Primary: Change in Body Satisfaction Questionnaire From Baseline to 4-Week Post-Treatment Follow-up Visit — 5.1; 5.5 Participants completed Questionnaire
Prostate Cancer
Primary: PRIMARY OBJECTIVES: I. To Determine the Impact of 18F-DCFPyL PET/CT on Initial and Subsequent Treatment Strategies of Patients With Prostate Cancer. — 66.2 Percent
Type 1 Diabetes · Peripheral Neuropathy
Primary: Skin Biopsy - Intraepidermal Nerve Fiber Density (IENFD) - Distal Thigh — 12; 14 Percentage change in IENFD
Obesity · Overweight · Weight Loss
Primary: (Feasibility) Engagement in Self-monitoring Body Weight — 89 % of intervention days
Rheumatoid Arthritis
Primary: Arthritis Self-Efficacy Scale (ASES) — 74; 74 score on a scale
Hiv
Primary: HIV-related Stigma — 8.74; 10.25; 7.16; 8.42 units on a scale
Uveitis
Primary: Corticosteroid-sparing Treatment Success Within the First 6 Months After Randomization — 0.69; 0.54 Cumulative proportion of participants — p=0.029
Body Fat Disorder
Primary: Number of Unanticipated Adverse Device Effects (UADE) — 0; 0; 0; 0 events